Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MOTUS GI HOLDINGS, INC.

(MOTS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MOTUS GI HOLDINGS, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)

09/08/2021 | 08:18am EDT

Item 7.01. Regulation FD.

On September 8, 2021, Motus GI Holdings, Inc. (the "Company") issued a press release announcing enrollment of patients at a second site in the European Union (EU) study of the Pure-Vu System, which is evaluating the clinical outcomes in patients with a history of poor bowel preparation using a low volume preparation with limited diet restrictions and the Pure-Vu System. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.


Item 8.01 Other Events.


On September 8, 2021, the Company announced the enrollment of patients at GastroZentrum Lippe, a private endoscopy clinic in Germany, the second site for the Company's European Union (EU) study of the Pure-Vu System, which is evaluating the clinical outcomes in patients with a history of poor bowel preparation using a low volume preparation with limited diet restrictions and the Pure-Vu System.

Germany is currently the largest colonoscopy market in Europe, with approximately 1.7 million procedures expected to be performed in 2021, according to iData Research Inc.

Item 9.01. Financial Statements and Exhibits.

(d) The following exhibit is furnished with this report:



Exhibit No.   Description
99.1            Press Release issued by Motus GI Holdings, Inc., dated September 8, 2021.
104           Cover Page Interactive Data File (embedded within the Inline XBRL document)




                                       1

© Edgar Online, source Glimpses

All news about MOTUS GI HOLDINGS, INC.
09/28MOTUS GI : Announces the Passing of Independent Director Dr. Sam Nussbaum
AQ
09/28Motus GI Holdings, Inc. Announces the Demise of Independent Director Dr. Sam Nussbaum
CI
09/13MOTUS GI : to Present at the Oppenheimer & Co. Inc. Fall Healthcare Summit
AQ
09/08MOTUS GI : Enrollment Begins for Motus GI's EU Study of Pure-Vu System
MT
09/08MOTUS GI : Announces Enrollment of Patients at Second Site in the European Union Outpatien..
PU
09/08MOTUS GI HOLDINGS, INC. : Regulation FD Disclosure, Other Events, Financial Statements and..
AQ
09/08Motus GI Holdings, Inc. Announces Enrollment of Patients At Second Site in the European..
CI
09/08MOTUS GI : Announces Enrollment of Patients at Second Site in the European Union Outpatien..
AQ
09/07MOTUS GI : to Participate in Two Upcoming Investor Conferences in September 2021
AQ
08/27MOTUS GI HOLDINGS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Ru..
AQ
More news
Analyst Recommendations on MOTUS GI HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 0,48 M - -
Net income 2021 -24,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,20x
Yield 2021 -
Capitalization 29,5 M 29,5 M -
Capi. / Sales 2021 61,6x
Capi. / Sales 2022 8,69x
Nbr of Employees 24
Free-Float 93,1%
Chart MOTUS GI HOLDINGS, INC.
Duration : Period :
Motus GI Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MOTUS GI HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 0,61 $
Average target price 2,03 $
Spread / Average Target 233%
EPS Revisions
Managers and Directors
Timothy P. Moran Chief Executive Officer & Director
Mark Pomeranz President, Chief Operating Officer & Director
Andrew L. Taylor Chief Financial Officer
David P. Hochman Chairman
Shervin Joe Korangy Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MOTUS GI HOLDINGS, INC.-35.52%29
THERMO FISHER SCIENTIFIC26.25%232 943
DANAHER CORPORATION36.93%220 224
INTUITIVE SURGICAL, INC.23.32%120 050
SIEMENS HEALTHINEERS AG37.92%75 570
EDWARDS LIFESCIENCES CORPORATION21.77%71 683